Ittmann M M, Cooper C
Biochem J. 1983 Apr 15;212(1):173-82. doi: 10.1042/bj2120173.
Very-low-density lipoprotein (VLDL), labelled in vivo with [9,10-3H]oleate, was taken up rapidly by liver after injection in vivo. Initially, radioactive lipoprotein remnants in the VLDL density range were present in liver as a bound extracellular pool that could be released by perfusion with polyphosphate or heparin. The bound remnant showed a decrease in mean diameter and an increased proportion of cholesteryl ester as a function of time after injection. When VLDL of different mean diameters was injected, it was found that: (1) total uptake by liver was independent of diameter; (2) small VLDL was not taken up more rapidly than large VLDL; and (3) Large VLDL lost no more triacylglycerol before binding than did small VLDL and larger species of mean diameter greater than 40 nm were bound. It is concluded that there is no unique VLDL remnant taken up by liver in vivo. When livers were perfused after binding radioactive VLDL in vivo, the lipoprotein was metabolized, with the production of water-soluble products, and this metabolism was inhibited by chloroquine.
用[9,10 - 3H]油酸在体内标记的极低密度脂蛋白(VLDL),在体内注射后被肝脏迅速摄取。最初,VLDL密度范围内的放射性脂蛋白残粒在肝脏中以结合的细胞外池形式存在,可通过用多磷酸盐或肝素灌注而释放。结合的残粒在注射后的一段时间内,平均直径减小,胆固醇酯比例增加。当注射不同平均直径的VLDL时,发现:(1)肝脏的总摄取量与直径无关;(2)小的VLDL摄取速度并不比大的VLDL快;(3)大的VLDL在结合前比小的VLDL失去的三酰甘油并不更多,且平均直径大于40nm的更大颗粒被结合。结论是体内肝脏摄取的并非单一的VLDL残粒。当在体内结合放射性VLDL后对肝脏进行灌注时,脂蛋白会被代谢,产生水溶性产物,且这种代谢会被氯喹抑制。